Shane J. Schaffer, PharmD
Chairman, Chief Executive Officer
Shane J. Schaffer, PharmD is a Co-Founder of Cingulate Therapeutics and has served as the Chairman and CEO since its inception. Dr. Schaffer is a 20-year pharmaceutical industry veteran with experience in pharmaceutical drug development, commercialization and biotech commercial operations. During his career, he has held positions at Pfizer, Novartis and Sanofi (including predecessor companies).
Dr. Schaffer has broad functional and therapeutic expertise through the development and commercialization of several billion dollar brands including the ADHD Franchise of Ritalin® & Focalin®, Lipitor®, Lyrica®, Eligard®, Arixtra®, Hyalgan® and Avapro®/Avalide®. He has led the strategic brand planning, franchise resource allocation and managed care & reimbursement strategy for numerous products.
Dr. Schaffer received his Doctor of Pharmacy degree from the University of Kansas. He served as Chief Fellow and completed a Post-Doctoral Pharmaceutical Industry Fellowship at Rutgers University, College of Pharmacy in conjunction with Warner-Lambert/Parke-Davis, now Pfizer.
Raul R. Silva, MD
Chief Science Officer
Raul R. Silva, MD is a Co-Founder of Cingulate Therapeutics and serves as CSO. He is a practicing child and adolescent psychiatrist who has served as Associate Professor and Vice Chairman of Child and Adolescent Psychiatry at New York University School of Medicine in New York City. Prior to that, he was the Executive Director of Rockland Children’s Psychiatric Center. He also served as the Deputy Director in the Division of Child and Adolescent Psychiatry at Bellevue Hospital Center, also in New York City.
Dr. Silva has authored/coauthored over 125 publications and presented at grand rounds and national meetings on over 120 occasions. He has been Principal Investigator and Co-Investigator for 21 research projects in his field.
Dr. Silva received his Doctor of Medicine degree from Ross University. He completed his fellowship in child and adolescent psychiatry at Columbia University’s St. Luke’s/Roosevelt Hospital Center where he became the director of service and residency training director. Dr. Silva completed a psychopharmacology research fellowship at New York University Medical Center. Dr. Silva is board certified in general, child and adolescent psychiatry.
Matthew Brams, MD
Chief Medical Officer and Member, Board of Directors
Matthew Brams, MD is Chief Medical Officer, a Co-Founder of Cingulate Therapeutics, and member of the Board of Directors. Dr. Brams is Medical Director and Principal of Bayou City Research, Inc. There, he has been instrumental in gaining FDA approval of over 15 Central Nervous System drugs currently in the marketplace. Dr. Brams is also a Clinical Associate Professor at the Menninger Department of Psychiatry of Baylor College of Medicine and has published over 20 peer-reviewed journal articles.
He has been lead investigator in several pivotal trials involving drugs in ADHD, autism, bipolar disorder and schizophrenia therapeutic areas. He has extensive experience in drug development and execution of Phase I-IV trials and has been involved in over 125 clinical trials in both adult and pediatric populations in all areas of psychiatry. In addition, he has over 25 years of clinical experience managing patients in the field of Adult and Child Psychiatry with particular expertise in ADHD and Autistic Spectrum Disorders (ASD).
He earned his MD from the University of Texas Health Science Center in Houston and completed his residencies at Baylor College of Medicine. He is Board certified in Adult and Child Psychiatry and is a Senior Board Examiner for the American Board of Psychiatry and Neurology.
Louis G. Van Horn, MBA, CPA
Chief Financial Officer
Louis G. Van Horn serves as CFO. Mr. Van Horn is a strategic finance leader whose business acumen is based over 35 years of experience as a strategic finance leader serving in executive leadership roles with a variety of industries including pharmaceuticals as well as Big 4 CPA experience.
Prior to Cingulate, Mr. Van Horn was Executive Vice President and Chief Financial Officer for eleven years with Store Financial Services, LLC. During his tenure he led the finance organization, while also at points serving as chief operating officer and on the board of directors. Prior to Store Financial, he was Vice President & Comptroller (Chief Accounting Officer) for Kansas City Southern, a NYSE company, for sixteen years. Earlier in his career, he worked in finance and accounting roles with Shell Oil Company, Yellow Freight Systems and PricewaterhouseCoopers. Mr. Van Horn has extensive corporate and not-for-profit board experience and was recognized by the Kansas City Business Journal as Chief Financial Officer of the Year in 2012.
Mr. Van Horn holds a Master’s degree in Business Administration, with distinction, from the Bloch School of Business at the University of Missouri – Kansas City and a Bachelor’s degree in Accounting from Westminster College in Fulton, Missouri. He is a Certified Public Accountant, a member of the Institute of Certified Public Accountants and Financial Executives International.
Laurie Myers, PhD, MBA
Senior Vice President, Operations and Member, Board of Directors
Laurie A. Myers, Ph.D is a pharmaceutical executive and entrepreneur whose expertise spans all aspects of branded pharmaceutical life cycle management from drug development and commercialization to strategy and execution of global marketing plans.
Dr. Myers therapeutic expertise includes cardiovascular disease/thrombosis, osteoarthritis and oncology with additional aptitude in infectious disease, neurology/psychiatric disorders and asthma. She has played key role in drug development, marketing and commercialization for leading global pharmaceutical companies, including Novartis, DuPont, Pfizer and Sanofi (including predessor companies) which included leadership positions in both R&D and marketing. She has been named to the Top 100 Brand Champions by Pharma Voice.
Dr. Myers is a founding member of the Cingulate Therapeutics Board of Directors and has contributed to two investor organizations; Mid Atlantic Bio Angels and Mid Atlantic Diamond Ventures and was commercial advisor to another start-up, EpiGen Pharma.
Dr. Myers earned her PhD in Toxicology from Rutgers Medical School/Rutgers School of Pharmacy in New Jersey and an MBA in Pharmaceutical Marketing from St. Joseph’s University, Philadelphia, PA. She has served as Adjunct Professor at The College of New Jersey School of Business.
Craig S. Gilgallon, Esq.
Craig S. Gilgallon is a Co-Founder of Cingulate Therapeutics and serves as General Counsel. As general counsel, he directs and manages all aspects of the company’s legal needs and corporate governance. Concurrently, Craig S. Gilgallon is one of the founding members and partner of Pawar Gilgallon & Rudy, LLC, a full-service business practice where he is dedicated to the efficient handling of transactional matters.
Mr. Gilgallon has more than ten years of experience in transactional and corporate law. He has advised and represented clients from mid-sized and early stage to larger multi-nationals in many type and size transactions, including mergers, acquisitions, divestitures, corporate recapitalizations, restructurings and reorganizations; alternative entities (partnerships, limited liability companies, business trusts, etc.); joint ventures and employment, licensing and other corporate arrangements; private and public placements of debt and equity securities; private equity investments; initial public offerings; domestic tax-advantaged transactions; project finance; etc.
Mr. Gilgallon received a B.A. from Ithaca College and received his Juris Doctorate from the Thomas Jefferson School of Law.
Stephen Abele, – BA Chemistry
Vice President of Manufacturing and Development
Stephen Abele serves as the Vice President of Manufacturing and Development where he oversees the development of Cingulate’s proprietary precision timed release platform technology. He brings over three decades of experience in the pharmaceutical industry and has developed and commercialized new oral solid dosage products in numerous forms including: Immediate Release, Controlled Release; Enteric, Sustained Release, Extended Release, Multi-Particulate and Tablet.
Prior to Cingulate, Mr. Abele led all development activities for the Optidose™ Platform and other Modified Release Technologies projects as an MRT Platform Lead at Catalent Pharma Solutions. Earlier, he held the position of Principal Pharmaceutical Process Specialist at Merck and Schering-Plough Corporation performing the responsibilities of Manufacturing Technical Support and development of new line extensions/technology transfers to the Kenilworth site. During that time, he led the conversion of the manufacturing processes for Claritin-D®24 tablet (a fixed dose combination product utilizing separate extended release with an immediate release, increasing operational efficiency and dramatically reducing cost. In addition, he oversaw Technology Transfer and scale-up of the tablet-in-tablet manufacturing process for Claritin-D®12 from a generic vendor to in-house manufacturing to prepare the products for over-the-counter sales.
Mr. Abele has also worked in generic manufacturing operations at Time Cap Labs and PureTek Corporation, as well as developing the technology for functional coating of nutritional supplements used today at Watson, Inc. formerly Watson Foods. He graduated Cum Laude from Ithaca College with a degree in Chemistry.